AbbVie Collaborates with Dragonfly Therapeutics to Develop Therapies for Autoimmune and Oncology Indications

AbbVie Collaborates with Dragonfly Therapeutics to Develop Therapies for Autoimmune and Oncology Indications

Shots:

  • Dragonfly to receive upfront, milestones and royalties on licensed therapies. AbbVie to get an exclusive option to license global intellectual property rights to develop and commercialize therapies developed during the collaboration
  • Dragonfly will utilize its TriNKET platform for developing therapies targeting multiple autoimmune and oncology indications
  • Dragonfly’s novel TriNKET technology acts by enhancing immunotherapy utilizing NK cells, thus harnessing the body’s innate immune system to bring breakthrough cancer therapies

Click here to­ read full press release/ article | Ref: PRNewswire | Image: The Wall Street Journal